Novel approaches in search for biomarkers of cholangiocarcinoma

doi:10.3748/wjg.v28.i15.1508

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 15

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6494)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

432

WORD

HTML

3547

Figures (1-1)

221

Tables (1-3)

348

Sum=4634

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

258

Download

356

Sum=614

Publishing Process of This Article

Item

Count

Browse

388

Download

858

Sum=1246

Apr 21, 2022 (publication date) through Jul 27, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Apr 21, 2022; 28(15): 1508-1525
Published online Apr 21, 2022. doi: 10.3748/wjg.v28.i15.1508

Table 2 Proteins associated with favorable cholangiocarcinoma diagnostic potential

Protein	Comparison	SEN (%)	SPE (%)	AUC	Ref.
	Tissue
CYFRA 21-1	iCCA (n = 217) vs HC (n = 514) meta-analysis	81.0	86.0	0.904	[58]
DKK1	iCCA (n = 37) vs HC (n = 50)	75.7	100.0	0.872	[52]
DKK1 + CA19-9	iCCA(n = 79) vs HC (n = 160)	74.7	56.3	0.793	[60]
IL-6	CCA (n = 26), HCC (n = 26) and HC (n = 23)	73.0	92.0	0.875	[53]
MMP-7	CCA (n = 44) vs benign BTD (n = 36)	76.3	46.8	0.730	[56]
MMP-7	CCA (n = 59) vs benign BTD (n = 128)	75.0	78.0	0.840	[57]
MUC5AC	CCA (n = 49), benign BTD (n = 23), HC (n = 16)	71.0	94.7	0.909	[55]
OPN	CCA (n = 107) vs HC (n = 55)	87.5	100.0	0.964	[50]
S100A6	CCA (n = 112) vs HC (n = 42)	86.2	90.9	0.909	[51]
SSP411	CCA (n = 30), benign BTD (n = 13) and HC (n = 23)	90.0	83.3	0.913	[54]
TGF-β1	CCA (n = 45), other disease conditions related inflammation (n = 25) and HC (n = 45)	71.1	68.9	0.668	[78]
TSP-2 + CA19-9	dCCA (n = 51), pancreatic ductal adenocarcinoma (n = 52), benign pancreatic diseases (n = 27) and HC (n = 52)	79.0	96.0	0.920	[61]
uPAR	CCA (n = 118), and HC (n = 76)	95.3	89.7	0.969	[59]
Biomarker panel: S100A9, MUC5AC, TGF-β1, Ang-2, and CA19-9	CCA (n = 40), non-CCA (n = 40) and HC (n = 40)	95.0	90.0	0.975	[62]

AUC: Area under the curve; BTD: Biliary tract disease; CCA: Cholangiocarcinoma; dCCA: Distal CCA; HC: Healthy controls; HCC: Hepatocellular carcinoma; iCCA: Intrahepatic cholangiocarcinoma; SEN: Sensitivity; SPE: Specificity; CYFRA 21-1: Cytokeratin 19 fragment; DKK1: Dickkopf 1; IL-6: Interleukin 6; MMP-7: Metalloproteinase 7; MUC5AC: Mucin 5AC; OPN: Osteopontin; S100A6: S100 calcium binding protein A6; SSP411: Spermatogenesis-associated protein 20; TGF-β1: Transforming growth factor-β1; TSP-2: Thrombospondin-2; uPAR: Urokinase-type plasminogen activator receptor; S100A9: S100 calcium binding protein A9; Ang-2: Angiopoietin-2.

Citation: Mocan LP, Ilieș M, Melincovici CS, Spârchez M, Crăciun R, Nenu I, Horhat A, Tefas C, Spârchez Z, Iuga CA, Mocan T, Mihu CM. Novel approaches in search for biomarkers of cholangiocarcinoma. World J Gastroenterol 2022; 28(15): 1508-1525
URL: https://www.wjgnet.com/1007-9327/full/v28/i15/1508.htm
DOI: https://dx.doi.org/10.3748/wjg.v28.i15.1508